Erratum

Abstract

Journal of the American Geriatrics SocietyVolume 61, Issue 3 p. 478-478 ErrataFree Access Erratum This article corrects the following: Long-Term Use of Oseltamivir for the Prophylaxis of Influenza in a Vaccinated Frail Older Population Patrick H. Peters MD, Stefan Gravenstein MD, Paul Norwood MD, Veerle De Bock MD, Anthony Van Couter MD, Michael Gibbens BSc, Tony-Andrea Von Planta MSc, Penelope Ward MB, Volume 49Issue 8Journal of the American Geriatrics Society pages: 1025-1031 First Published online: December 21, 2001 First published: 15 March 2013 https://doi.org/10.1111/jgs.12250Citations: 1AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat The authors of the paper “Long term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail elderly population”, published in the Journal of the American Geriatrics Society in 2001, were recently made aware of a difference in the number of psychiatric events between the oseltamivir and placebo treatment arms from that used to write the original manuscript. The corrected information, to replace the original Table 4 of the publication, now includes psychiatric events (below). The error occurred in the misclassification of confusion, a neuropsychiatric event, reducing the count in the placebo treatment group by one, and increasing the count in the oseltamivir treatment group by one. The newly reported event was seen in an 82-year old man with a history of coronary artery and Parkinson's disease who became severely confused and was hospitalized on study day 27, at which time his anticoagulants and aspirin were stopped. Study medication was withdrawn on day 28. On study day 29 he was discharged and study medication was restarted. Mild confusion was reported from day 32 to day 34, but this resolved while the patient remained on oseltamivir. Both events were considered unrelated to study medication by the investigator. Although the reclassification results in a statistically significant difference between the two treatment groups on neuropsychiatric events (P = 0.046, Chi square), the frequency is sufficiently low that it does not impact or change the overall results or outcomes of the study or the clinical implications for this population. Corrected version of Table 4.1 Summary of Most Common Adverse Events During Treatment With Oseltamivir 75 mg or Placebo Once Daily for 6 weeks Placebo (n = 272) (%) Oseltamivir 75 mg (n = 276) (%) Fatigue 20 (7.4) 24 (8.7) Nasal congestion 20 (7.4) 20 (7.2) Cough 22 (8.1) 13 (4.7) Sore throat 18 (6.6) 7 (2.5) Headache 15 (5.5) 23 (8.3) Influenza-like illness 15 (5.5) 13 (4.7) Pyrexia 15 (5.5) 7 (2.5) Nausea 11 (4.0) 12 (4.3) Diarrhea 11 (4.0) 9 (3.3) Neuropsychiatric Events 4 (1.5) 12 (4.3) Vomiting 4 (1.5) 5 (1.8) Urinary tract infection 11 (4.0) 10 (3.6) Yours sincerely, Stefan Gravenstein, MD, MPH, CMD Professor of Medicine and Health Services, Policy and Practice The Warren Alpert Medical School of Brown University Providence, RI Patrick H. Peters, Jr., MD, PA Texas Medical Research Associates San Antonio, Texas Reference 1Peters P, Gravenstein S, De Bock VNorwood P, De Bock V, et al. Long term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail elderly population. J Am Geriatr Soc 2004; 49(8): 2025– 31. Google Scholar Citing Literature Volume61, Issue3March 2013Pages 478-478 ReferencesRelatedInformation